- Home
- GNTA vs DTIL Comparison
GNTA vs DTIL Comparison
Compare GNTA & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNTA
- DTIL
- Stock Information
- Founded
- GNTA 2014
- DTIL 2006
- Country
- GNTA Italy
- DTIL United States
- Employees
- GNTA N/A
- DTIL N/A
- Industry
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- DTIL Biotechnology: Pharmaceutical Preparations
- Sector
- GNTA Health Care
- DTIL Health Care
- Exchange
- GNTA Nasdaq
- DTIL Nasdaq
- Market Cap
- GNTA 62.9M
- DTIL 55.3M
- IPO Year
- GNTA 2021
- DTIL 2019
- Fundamental
- Price
- GNTA $3.05
- DTIL $4.67
- Analyst Decision
- GNTA Strong Buy
- DTIL Strong Buy
- Analyst Count
- GNTA 1
- DTIL 2
- Target Price
- GNTA $25.00
- DTIL $47.00
- AVG Volume (30 Days)
- GNTA 16.2K
- DTIL 73.3K
- Earning Date
- GNTA 01-01-0001
- DTIL 11-03-2025
- Dividend Yield
- GNTA N/A
- DTIL N/A
- EPS Growth
- GNTA N/A
- DTIL N/A
- EPS
- GNTA N/A
- DTIL N/A
- Revenue
- GNTA N/A
- DTIL $1,261,000.00
- Revenue This Year
- GNTA N/A
- DTIL N/A
- Revenue Next Year
- GNTA N/A
- DTIL $135.19
- P/E Ratio
- GNTA N/A
- DTIL N/A
- Revenue Growth
- GNTA N/A
- DTIL N/A
- 52 Week Low
- GNTA $2.56
- DTIL $3.61
- 52 Week High
- GNTA $7.28
- DTIL $10.64
- Technical
- Relative Strength Index (RSI)
- GNTA 38.04
- DTIL 50.63
- Support Level
- GNTA $2.56
- DTIL N/A
- Resistance Level
- GNTA $3.18
- DTIL $5.17
- Average True Range (ATR)
- GNTA 0.31
- DTIL 0.22
- MACD
- GNTA -0.06
- DTIL -0.22
- Stochastic Oscillator
- GNTA 25.00
- DTIL 90.33
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.